Advancing Biologics from the Lab to the Clinic

11-12 January 2010, Bussels, Belgium.
Advancing Biologics from the Lab to the Clinic event will provide essential perspectives from both industry, regulatory and scientific perspectives in terms of what are the factors preventing biologics from progressing further in development and the vital elements of a successful early stage strategy for biologic studies.

Attendees will achieve an advanced understanding of how to incorporate the specific biologic requirements into the strategic & operational planning for an early phase clinical trial that provides the best opportunity to save time, reduce risk, reduce costs and maximise product value.

Escalating biologic drug R&D costs combined with a decline in the output of new molecular entities making it to the market has resulted in many pharma and biotech companies re-evaluating their traditional approaches.

Clinical development for biologics is widely acknowledged as being potentially more expensive and risky than small molecule development. The clinical development program should focus on not only on the normal questions of safety and efficacy, but also cover the biologic activity of the product in humans: immunogenicity, optimum dosage levels, potential biomarkers to measure effects. To have the highest chance for success it also needs to factor in both the products characterization and preclinical programs. The unique properties of these highly distinct products must be considered to minimize risks, aid later product development and demonstrate product value at an early stage.

Why attend?

  • Meet experts directly involved in biologic trial design and implementation
  • Learn about the specific regulatory guidance and level of proof required to satisfy the governing bodies.
  • Understand the perspectives of all stakeholder involved, i.e. regulators, sponsors, CROs, SMOs, central labs and experienced biologic investigators.
  • Come to benchmark, share experience and help to develop a best-practice approach to biologic clinical development.
  • Build stronger relationships upon a better understanding of the challenges faced by each group, who are all vital to the planning and implementation of the study.

Who will benefit

  • Experienced executives from Pharma and Biotechs involved in Biologic development
  • VPs, Professors, Senior Directors and Managers
  • Discovery
  • Pre-Clinical Development
  • Exploratory development
  • Early phase clinical development
  • Clinical science
  • Clinical Operations
  • Clinical pharmacology
  • PK & PD
  • Drug safety & biomarkers
  • Translational medicine
  • Regulatory affairs

For further information and registration, please visit:
https://www.nextlevelpharma.com/events/view/advanced_biologics_from_the_lab_to_the_clinic

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...